1. Signaling Pathways
  2. GPCR/G Protein
  3. P2Y Receptor

P2Y Receptor

P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as ATP, ADP, UTP, UDP and UDP-glucose. To date, 12 P2Y receptors have been cloned in humans: P2Y1, P2Y2, P2Y4, P2Y5, P2Y6, P2Y8, P2Y9, P2Y10, P2Y11, P2Y12, P2Y13 and P2Y14. P2Y receptors are present in almost all human tissues where they exert various biological functions based on their G-protein coupling. P2Y2 is a potential drug target for treating cystic fibrosis. P2Y11 is a regulator of immune response, and a common polymorphism carried by almost 20% of North European caucasians give increased risk of myocardial infarction, making P2Y11 an interesting drug target candidate for treatment of myocardial infarction. P2Y12 is the target of the anti-platelet drug clopidogrel and other thienopyridines.

P2Y Receptor Related Products (31):

Cat. No. Product Name Effect Purity
  • HY-17459
    Clopidogrel hydrogen sulfate Inhibitor 99.67%
    Clopidogrel hydrogen sulfate is an antiplatelet agent which works by blocking platelets from sticking together and prevents them from forming harmful clots.
  • HY-B0606
    Diquafosol tetrasodium Agonist 99.93%
    Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.
  • HY-10064
    Ticagrelor Antagonist 99.98%
    Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
  • HY-13104
    MRS 2578 Antagonist
    MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
  • HY-N7032
    Uridine 5′-diphosphoglucose disodium salt Agonist 99.52%
    Uridine 5′-diphosphoglucose disodium salt (UDP-D-Glucose disodium salt) is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine-5′-diphosphoglucose is an agonist of the P2Y14 receptor, a neuroimmune system GPCR.
  • HY-111557
    YM-254890 Inhibitor
    YM-254890 is a selective Gαq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y1 signal transduction pathway, with an IC50 value below 0.6 μM.
  • HY-110322A
    PPTN Antagonist
    PPTN is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. Anti-inflammatory and immune activity.
  • HY-108648
    2-Methylthioadenosine diphosphate trisodium Agonist
    2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1.
  • HY-13831
    BPTU Antagonist 99.84%
    BPTU is a novel P2Y1 allosteric antagonist.
  • HY-15799
    AZD1283 Antagonist 99.11%
    AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.
  • HY-15876
    Clopidogrel thiolactone Inhibitor >98.0%
    Clopidogrel thiolactone is a P2Y12 receptor inhibitor, is a potent antiplatelet agent.
  • HY-18775
    N6-(4-Hydroxybenzyl)adenosine Inhibitor 99.66%
    N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM).
  • HY-15284
    Prasugrel Inhibitor >98.0%
    Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
  • HY-W010832
    Uridine-5'-diphosphate disodium salt Modulator 99.59%
    Uridine-5'-diphosphate disodium salt is a potent, selective P2Y6 receptor native agonist (EC50=300 nM; pEC50=6.52) and a potent P2Y14 antagonist (pEC50=7.28). Uridine-5'-diphosphate disodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis.
  • HY-15284A
    Prasugrel hydrochloride Inhibitor 99.57%
    Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and prodrug, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
  • HY-15283
    Clopidogrel Inhibitor
    Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
  • HY-111755
    Oral antiplatelet agent 1 Antagonist
    Oral antiplatelet agent 1 is a potent antiplatelet agent with an IC50 of 2.94 μM in vitro as well as antithrombotic efficacy in a rat model. P2Y receptor antagonist.
  • HY-108672
    NF157 Antagonist
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively. NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA).
  • HY-118284
    Vicagrel Inhibitor 98.55%
    Vicagrel, an acetate derivative of Clopidogrel, is a P2Y12 platelet inhibitor potentially for the treatment of thrombosis, the substrate of carboxylesterase 2 (CES2). Vicagrel demonstrates a favorable safety profile and excellent anti-platelet activity, which could be an anti-platelet drug and for the unmet medical needs of cardiovascular diseases.
  • HY-108661
    NF546 Agonist
    NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.